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Abstract: 
We evaluated the Hain GenoQuick® (GQM) methicillin resistant 
Staphylococcus aureus (MRSA) assay for the rapid detection of 
MRSA using one swab, i.e. the same screening specimen was used 
first for MRSA culture and then for rapid testing by PCR, as this 
would be the preferred option for routine diagnostic testing. GQM 
detected current prevalent Irish MRSA strains incorporating all 
known SSCmec types including Panton-Valentine leukocidin positive 
strains. All methicillin resistant coagulase negative staphylococci 
tested were negative but three of seven gentamicin-resistant MSSA 
strains tested were identified as MRSA by the GQM method.  
The theoretical ex-vivo limit of detection of the assay was 704 
colony forming units (CFU) per GQM assay reaction 
(1.7x104CFU/ml) when MRSA suspensions were used for DNA 
extraction or 1.4x103 CFU/swab (1.4x104 CFU/ml) using MRSA 
absorbed onto Copan screening swabs. We demonstrated that swab 
processing on chromogenic agar prior to PCR resulted in some 
inhibition of the PCR reaction, increasing the limit of detection of 
the assay by a factor of 4. Based on the processing of 540 
screening specimens (nasal and groin) by culture first and GQM 
second, the specificity and positive predictive value were both 
100%, the negative predictive value was 92%, and the sensitivity 
was 57%. Culture followed by PCR from one specimen is not 
optimal for the rapid detection of MRSA. Further laboratory 
validation of the GQM assay is required to determine the true 
diagnostic sensitivity and value of this kit in routine microbiology 
laboratories, either with PCR before culture or using two specimens.  





































































MRSA Screening: Can one swab be used for both culture and rapid testing? 1 
An evaluation of chromogenic culture and subsequent Hain GenoQuick® PCR 2 
amplification/detection.  3 
 4 
O. Sherlock,a,*, 1 A. Dolan,a, 1 H. Humphreys,a,b  5 
 6 
aDepartment of Clinical Microbiology, Education and Research Centre, Royal College of 7 
Surgeons in Ireland, Dublin, Ireland. 8 
bDepartment of Microbiology, Beaumont Hospital, Dublin, Ireland. 9 
 10 
*Corresponding author’s address: Department of Clinical Microbiology, RCSI Education 11 
and Research Centre, Beaumont Hospital, PO Box 9063, Beaumont Road, Dublin 9, 12 
Ireland. Tel.: +353 1 8093728; fax +353 1 8093709. 13 
E-mail address: orlasherlock@rcsi.ie 14 
 15 
Keywords: MRSA, Rapid Detection, PCR, Screening specimens. 16 
 17 
Running Title:  MRSA Screening; two tests one swab.  18 
1
 Authors contributed equally to the paper 19 
 20 
Word Count:  Abstract (250), Main Body Text excluding acknowledgements (2500) 21 
 22 
 23 































































Abstract  24 
We evaluated the Hain GenoQuick® (GQM) methicillin resistant Staphylococcus 25 
aureus (MRSA) assay for the rapid detection of MRSA using one swab, i.e. the same 26 
screening specimen was used first for MRSA culture and then for rapid testing by PCR, 27 
as this would be the preferred option for routine diagnostic testing. GQM detected current 28 
prevalent Irish MRSA strains incorporating all known SSCmec types including Panton-29 
Valentine leukocidin positive strains. All methicillin resistant coagulase negative 30 
staphylococci tested were negative but three of seven gentamicin-resistant MSSA strains 31 
tested were identified as MRSA by the GQM method.  32 
The theoretical ex-vivo limit of detection of the assay was 704 colony forming 33 
units (CFU) per GQM assay reaction (1.7x104CFU/ml) when MRSA suspensions were 34 
used for DNA extraction or 1.4x103 CFU/swab (1.4x104 CFU/ml) using MRSA absorbed 35 
onto Copan screening swabs. We demonstrated that swab processing on chromogenic 36 
agar prior to PCR resulted in some inhibition of the PCR reaction, increasing the limit of 37 
detection of the assay by a factor of 4. Based on the processing of 540 screening 38 
specimens (nasal and groin) by culture first and GQM second, the specificity and positive 39 
predictive value were both 100%, the negative predictive value was 92%, and the 40 
sensitivity was 57%. Culture followed by PCR from one specimen is not optimal for the 41 
rapid detection of MRSA. Further laboratory validation of the GQM assay is required to 42 
determine the true diagnostic sensitivity and value of this kit in routine microbiology 43 
laboratories, either with PCR before culture or using two specimens.  44 
 45 
 46 































































Introduction  47 
A major component of the control of methicillin-resistant Staphylococcus aureus 48 
(MRSA) transmission is the early detection of patients either colonised or infected with 49 
MRSA, followed by isolation to prevent cross-infection [1]. Several publications 50 
evaluating the accuracy of various MRSA detection kits (IDI MRSA, GeneXpert MRSA, 51 
GenoType® MRSA and the MRSA EVIGENETM ) and PCR in-house assays [2-8] have 52 
been published. The Hain GenoQuick® (GQM) methicillin resistant Staphylococcus 53 
aureus (MRSA) assay (Hain Lifescience, Nehren, Germany) is a new molecular assay. Its 54 
predecessor GenoType® MRSA is a PCR assay using DNA Strip® technology for 55 
amplicon detection, and permits the identification of S. aureus, S. epidermidis, and the 56 
mecA gene, with a specimen turn around time of approximately seven hours [7, 9,]. GQM 57 
is based on the same immuno-chromatographic detection technology, but detects MRSA 58 
only with a reported turn around time of approximately two and a half hours. MRSA 59 
specific chromosomal sequences are targeted. The assay consists of three steps: direct 60 
DNA extraction from a patient swab using a lysis buffer provided, followed by multiplex 61 
PCR (primer/probe/nucleotide mix provided) with single stranded amplicon hybridization 62 
using a specific probe and finally, the detection of amplicon/probe complex - the complex 63 
selectively binds to the test band on the dipstick and is visualized by gold labeling.  Each 64 
dipstick includes two control zones, a conjugate control zone to check the binding of the 65 
conjugate on the dipstick and an amplification control zone to check for a successful 66 
amplification reaction.  67 
Here we determined the accuracy and the limit of detection (LoD) of the GQM 68 
assay and established the potential to use one MRSA screening swab for two methods of 69 































































MRSA detection. This specimen process flow is preferred where diagnostic laboratories 70 
choose to continue culture with PCR, for confirmation and to use the isolate for 71 
epidemiological purposes.  Additionally, this specimen flow enabled adherence to 72 
accredited laboratory standard operating procedures, minimised the additional 73 
nursing/laboratory and administrative workloads, and the financial burden associated 74 
with the taking and processing of two specimens. 75 
 76 
Methods  77 
Bacterial isolates  78 
The capacity of the GQM assay to detect Irish MRSA strains (n=32) was assessed 79 
with a collection provided by the National MRSA Reference Laboratory, Dublin and 80 
Dublin Dental School and Hospital, Trinity College Dublin [10,11].  All isolates were 81 
tested according to manufacturer’s instructions for pure culture testing. This isolate group 82 
comprised of 27 isolates representative of common epidemiological types recovered in 83 
Ireland and four control strains, including the following SCCmec types (I, IA, II, IIA-IIE, 84 
III, IIIv, IV and IVa-IVh, V, VI). Two reference strains, MRSA-ATCC 43300 and 85 
methicillin sensitive Staphylococcus aureus (MSSA)-ATCC 29213 were included. A 86 
further seven gentamicin-resistant methicillin-susceptible Staphylococcus aureus 87 
(GrMSSA) strains [12] and eight various methicillin resistant coagulase negative 88 
staphylococci (MRCNS) were also tested.  89 
 90 
Conventional culture and MRSA identification 91 
MRSA screening specimens were collected using single Copan 151C cotton albumin 92 
coated swabs (Medical Supply Company, Ireland) as per laboratory standard operating 93 































































procedures. The GQM assay does not specify what type of swab is optimal for use. 94 
Swabs were assessed for the presence of MRSA by plating on MRSA Select® 95 
chromogenic media (CA) for the isolation and identification of MRSA (Bio-Rad Life 96 
Science Group, France). Colonies deemed positive on this media were subcultured on 97 
Columbia Blood Agar (CBA) (Cruinn, Ireland) and confirmed by slide coagulase 98 
(Staphaurex Plus, Remel, Oxoid Ltd., U.K.) and by automated antibiotic susceptibility 99 
testing (Phoenix, BD Biosciences, USA).  100 
 101 
Limit of detection (LoD) assays 102 
LoD assays (n=3) of the GQM assay were performed as follows: A 0.5 McFarland 103 
of strain MRSA ATCC 43300 was prepared in saline and a 10-fold dilution series carried 104 
out. CFU/ml was determined by spread plating each dilution on CBA in and incubating at 105 
37°C for 24 h. 106 
To calculate the LoD of the assay when MRSA suspensions were used directly for 107 
DNA extraction protocols.40 µl of each dilution above was added to 260 µl of buffer Q-108 
LYS supplied in the GQM kit. Subsequent extraction of these 300 µl preparations, PCR 109 
and ELISA based detection were performed as per the manufacturers’ instructions.  110 
To calculate the LoD when MRSA suspensions were absorbed onto Copan 111 
screening swabs prior to DNA extraction 100 µl of each dilution above was adsorbed 112 
onto an individual swab. The swab was allowed to dry for 30 min before vigorous 113 
vortexing in 300 µl  of buffer Q-LYS and GQM processing.  114 
Using the CFU/ml count determined above, the LoD of each reaction was 115 
determined, and the equivalent CFU/ml was calculated. LoD were recorded as the lowest 116 
concentration which produced a GQM assay positive reaction. 117 
 118 
Deleted: when cells were added 
directly to the PCR reaction, 4
Deleted: where cells were absorbed 
onto Copan screening swabs prior to PCR 
amplification, 































































GQM assay inhibition by CA agar  119 
 To establish if culturing screening specimens on CA prior to GQM processing 120 
resulted in any PCR reaction inhibition the following experiment was carried out (n=3). 121 
A 10-fold dilution series of a 0.5 McFarland S. aureus ATCC 43300 was made in 1ml 122 
volumes of sterile saline. 40 µl of each dilution was added to 260 µl of GQM buffer Q-123 
LYS. A duplicate set of dilutions was prepared. In the first set, a sterile Copan swab was 124 
rubbed on a CA plate just before washing in each 300 µl dilution and processing by 125 
GQM. In the second set, a sterile Copan swab that had not been exposed to CA agar was 126 
washed in each 300 µl dilution and processed by GQM. The number of CFU per dilution 127 
was determined by spread plating (as for LoD above). LoD results were compared to 128 
determine if rubbing the swab on CA prior to PCR had an inhibitory affect. 129 
 130 
GQM version 2.0  131 
All tests were performed according to the manufacturer’s instructions except that 132 
specimens were cultured on CA prior to washing the swab in lysis buffer. The PCR 133 
amplification mix consisted of 35 µl primer nucleotide mix, 5 µl 10x polymerase buffer, 134 
0.5 µl of 25mM MgCl2  0.3 µl Fast start Taq (5u per µl) (Roche), 5 µl DNA template and 135 
4.2 µl water. The amplification protocol was according to the manufacturers instructions.  136 
 137 
Patient specimen collection and processing 138 
Nasal and groin swabs were collected from patients on various hospital wards in a 139 
700-bed tertiary referral hospital with endemic MRSA, over an eight week period as part 140 




Chromogenic agar (CA) inhibition































































patients were collected and processed (270 groin and 270 nasal). Swabs were cultured on 142 
CA plates before processing by GQM. Discrepant results were further examined as 143 
follows.  Swabs that were PCR positive, culture negative were cultured a second time, but 144 
were enriched overnight in 5 ml of tryptone salt broth 6% NaCl (37°C at 150 rpm in a 145 
shaking incubator) with subsequent plating on CA. Specimens that were PCR negative, 146 
culture positive were processed again by PCR i.e. as per manufacturer’s instruction 5 µl 147 
of the 300 µl extracted specimens were tested a second time by GQM PCR. Additionally, 148 
the MRSA isolate recovered from the discrepant specimen was tested by PCR in pure 149 
culture as per manufacturer’s instructions. 150 
 151 
Results 152 
Analytical sensitivity and specificity 153 
The GQM assay detected all MRSA strains in a collection representative of 154 
MRSA in Ireland since 1974 (n=32). All eight MRCNS tested negative.  Of seven 155 
GrMSSA strains tested, 3 tested positive by PCR and are considered false positives.  156 
 157 
LoD assays 158 
 Using a saline dilution series and plate counting, the LoD when MRSA 159 
suspensions were used directly for DNA extraction and subsequent GQM amplification 160 
was determined to be 704 CFU/GQM reaction (equivalent to a calculated 1.7x104 161 
CFU/ml). As only 5 µl of the extracted 300 µl DNA preparations can be used as template 162 
in the GQM PCR reaction, it can be said the LoD per PCR is 11.8 CFU. 163 































































The LoD when MRSA suspensions were absorbed onto Copan screening swabs 164 
prior to DNA extraction and subsequent GQM amplification was determined to be 165 
1.4x103 CFU/swab equivalent to a calculated 1.4x104 CFU/ml.  166 
 167 
Chromogenic agar inhibits the Hain® GQM assay 168 
 In a GQM reaction where a swab was washed in GQM buffer Q-LYS containing a 169 
known number of MRSA cells, the lowest number of MRSA detected was 1,390 170 
CFU/reaction. In contrast, where the swab was first rubbed on a CA plate and then 171 
washed in GQM buffer Q-LYS containing the same number of MRSA cells as above, the 172 
lowest number of MRSA detected was 5,560 CFU/reaction, suggesting processing of 173 
swabs on CA prior to GQM PCR does have an inhibitory effect and increases LoD per 174 
reaction or CFU/ml by a factor of 4 (approximately).  175 
 176 
Clinical specimens 177 
Of 540 specimens processed 47/540 (8.7%) were both PCR and culture positive 178 
and 451/540 (83.5%) were negative by both methods. Discrepant results occurred with 179 
42/540 (7.7%) specimens; 4 were PCR positive but culture negative and 38 were PCR 180 
negative but culture positive. All four patients with a positive PCR and culture negative 181 
result had been decolonised and thus were considered true MRSA positives. The 182 
amended MRSA positive rate was therefore calculated as 51/540 (9.4%), with a 183 
discrepant rate of 38/540 (7.0%). For these remaining 38 discrepant results (PCR 184 
negative/culture positive specimens), PCR rechecks of the prepared DNA extracted/lysis 185 
reactions were carried out and all were confirmed negative.  186 































































All 38 swabs were plated a second time on CA and subsequently enriched in TSB 187 
broth for 24 h followed by plating on CA. Twelve grew after direct plating and 188 
enrichment, suggesting the microorganisms were present on the swabs but were not 189 
detected by PCR. PCR on all 12 of these isolates (colony tested) were PCR positive, 190 
therefore these were considered true PCR false negatives. S. aureus was not isolated 191 
again after repeat culture with enrichment in TSB for the remaining 26/38 discrepant 192 
specimens. These were considered false negatives. The sensitivity, specificity, positive 193 
predicative value (PPV) and negative predictive value (NPV) were calculated (Table 1). 194 
 195 
Discussion  196 
Conference proceedings by Eigner et al [13] report on an evaluation of the GQM 197 
assay and report this assay as 100% sensitive, with a specificity of 99.4%, PPV 96% and 198 
NPV 100% while Boegli-Stuber [14] report a GQM sensitivity of 91.3%. These results 199 
were promising as GQM was 50% cheaper than other molecular methods, it could 200 
provide a cost effective alternative for rapid MRSA diagnostics. Additionally this study 201 
showed that GQM detects SCCmec types I-V, while MSSA or coagulase negative 202 
Staphylococci test negative. Our data supports this, with SCCmec VI also being detected.  203 
However, three of seven GrMSSA strains tested here produced a GQM positive, culture 204 
negative result. These strains [12] harbor remnants of SCCmec DNA. As the majority of 205 
commercially available assays use PCR to detect SCC-associated sequences directly from 206 
clinical specimens, a PCR positive/culture negative results warrants caution and further 207 
investigation, e.g. culture on non selective media for isolate characterisation.  208 































































The LoD of GQM can be reported in a number of ways. Here we established the 209 
LoD of the complete GQM assay to be 704 CFU. This is the minimum number of MRSA 210 
cells required to be added to the GQM extraction mix that will result in a positive 211 
hybridization signal. LoD can also be expressed as LoD per PCR and has this has been 212 
calculated as 11.8 CFU per PCR. As many studies report LoD of rapid assays in CFU per 213 
ml or CFU per swab these GQM LoD results can also be reported as 1.4x104 CFU/ml or 214 
1.7 x103 CFU/swab. By contrast, the LoD of other rapid methods have been reported as 215 
6.1 x102 CFU/ml or 5.8 x101 CFU/swab for GeneXpert and 1.7x102 CFU/swab for 216 
routine MRSA chromogenic culture [4].  217 
Processing clinical specimens on CA and subsequent GQM amplification as 218 
described here results in a discrepant rate of 7% (38 specimens were PCR negative, 219 
culture positive). Twelve of the 38 discrepant specimens reported as PCR negative/ 220 
culture positive, were culture positive both prior to GQM processing and when cultured a 221 
second time after discharge in the Q-LYS lysis buffer, suggesting that these were false 222 
negatives by GQM.  223 
However, 26/38 specimens that were culture positive/PCR negative were not 224 
found to be culture positive after a second attempt to culture them following discharge in 225 
the GQM buffer Q-LYS solution. Some possible explanations for these discrepancies 226 
include: (i) discrepancy due to this workflow i.e. processing by culture before GQM 227 
removed all organisms from the swab hence a GQM negative result (ii) PCR inhibition 228 
resulted from rubbing the swab on a CA plate prior to GQM processing (iii) the lysis 229 
reaction may have failed or may not have been optimal but there is no control for this 230 
reaction when using the GQM kit and (iv) these 26 specimens were not detected as GQM 231 































































positive because inoculum levels were below the LoD of the GQM assay. Depending on 232 
the interpretation of these findings various sensitivities could be calculated. If we 233 
excluded the 26 specimens from sensitivity calculations that were GQM negative, culture 234 
positive from the analysis, assuming that because of the work flow used all organisms 235 
had been removed by culture prior to PCR or CA inoculation resulted in inhibition, a 236 
GQM sensitivity of 81% would be achieved. If we included the 26 specimens in the 237 
sensitivity calculation but assumed that all 26 specimens would have been PCR 238 
positive/culture positive if specimens had been processed by PCR first followed by 239 
culture, then an improved sensitivity of 87% would result. However, the actual sensitivity 240 
determined here was 57%. The true value for the sensitivity value is at best between 241 
81%-87% but at worst between 57-81%, depending on the interpretation of the PCR 242 
negative culture positive discrepant results. A full study to establish the diagnostic 243 
sensitivity of Hain GQM would be valuable.  244 
We acknowledge the limitations in our evaluation which include the number of 245 
specimens tested, confining the testing to nasal and groin specimens only (other licensed 246 
specimens include throat and wounds), the taking of only one specimen per site for both 247 
PCR and culture and the processing of this specimen by culture prior to PCR instead of 248 
vice-versa. While an evaluation of two swabs per site, i.e. one for PCR and one for 249 
culture might have led to fewer discrepant results, this represents considerable additional 250 
processing time and expense for routine diagnostic laboratories. Additionally, we did not 251 
want to alter the accredited method of culture as this was an evaluation in a routine 252 
diagnostic setting, thus minimizing any deviations from normal practice was important.  253 
Furthermore, discrepancies may still have occurred if two specimens had been taken, e.g. 254 































































due to a greater load of MRSA being swabbed with the first specimen compared with the 255 
second. However, for evaluations of new diagnostic methods the additional expense and 256 
time should be incurred.  257 
In summary, while agreement of results occurred for 92.3% of specimens 258 
processed with culture first followed by PCR, the number of discrepant results, and 259 
questions posed by these results suggest that culture followed by PCR using the one swab 260 
is not suitable for routine use. It is unclear if an alternative swab processing regime, i.e. 261 
PCR followed by culture would overcome these shortcomings but this may result in a 262 
reduced yield from culture. Consequently it is likely that where both culture and PCR are 263 
being used, two swabs need to be taken with the resulting time and expense incurred.  264 
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Positive  51 38 57 100 100 92 
Negative 0 451     
 332 
Table 1: Sensitivity, specificity, PPV and NPV of the Hain GQM assay.  333 
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